PMID- 22074845
OWN - NLM
STAT- MEDLINE
DCOM- 20120716
LR  - 20120319
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 21
IP  - 4
DP  - 2012 Apr
TI  - Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis.
PG  - 412-20
LID - 10.1177/0961203311427550 [doi]
AB  - The prevalence of autoantibodies in multiple sclerosis (MS) patients and their 
      clinical associations differ between various studies. This study investigated 
      antiphospholipid and antinuclear antibodies in 85 patients with multiple 
      sclerosis (MS) and clinically isolated syndrome (CIS) with regard to their 
      association with demographic features, MS specific clinical features and symptoms 
      of connective tissue diseases. Autoantibodies tested included antinuclear 
      antibodies (ANA) with their specificities and anticardiolipin (aCL) and 
      anti-beta-2-glycoprotein I (anti-beta2GPI) antibodies. Antinuclear antibodies were 
      more prevalent in MS patients than in controls (63.5% vs. 3.3%; p < 0.01) and in 
      19% of patients specific antinuclear antibodies were detected. Anti-beta2GPI IgM 
      antibodies were more frequent in MS patients than in the control group (20% vs. 
      3.3%; p < 0.05). The frequency of anticardiolipin antibodies did not differ 
      between MS patients and controls. MS patients seropositive for ANA and 
      extractable nuclear antigens (ENA) had significantly shorter disease duration 
      than seronegative patients (p < 0.05) and a lower disability score (Expanded 
      Disability Status Score; EDSS) (p < 0.05). Anti-beta2GPI antibodies were more 
      frequent in patients with secondary progressive MS (SP-MS) and specific ANA 
      antibodies were more frequent in patients with clinically isolated syndrome (CIS) 
      (p < 0.05). The presence of autoantibodies was not associated with the 
      predominant site of neurological involvement or the clinical features of 
      connective tissue diseases.
FAU - Szmyrka-Kaczmarek, M
AU  - Szmyrka-Kaczmarek M
AD  - Department of Rheumatology and Internal Diseases, Wroclaw Medical University, 
      Poland. magda_szmyrka@yahoo.com
FAU - Pokryszko-Dragan, A
AU  - Pokryszko-Dragan A
FAU - Pawlik, B
AU  - Pawlik B
FAU - Gruszka, E
AU  - Gruszka E
FAU - Korman, L
AU  - Korman L
FAU - Podemski, R
AU  - Podemski R
FAU - Wiland, P
AU  - Wiland P
FAU - Szechinski, J
AU  - Szechinski J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111110
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Antibodies, Antiphospholipid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Antinuclear/*blood
MH  - Antibodies, Antiphospholipid/*blood
MH  - Case-Control Studies
MH  - Chi-Square Distribution
MH  - Connective Tissue Diseases/blood/diagnosis/*immunology
MH  - Disability Evaluation
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Chronic Progressive/blood/diagnosis/*immunology
MH  - Multiple Sclerosis, Relapsing-Remitting/blood/diagnosis/*immunology
MH  - Poland
MH  - Prognosis
MH  - Serologic Tests
MH  - Severity of Illness Index
MH  - Young Adult
EDAT- 2011/11/15 06:00
MHDA- 2012/07/17 06:00
CRDT- 2011/11/15 06:00
PHST- 2011/11/15 06:00 [entrez]
PHST- 2011/11/15 06:00 [pubmed]
PHST- 2012/07/17 06:00 [medline]
AID - 0961203311427550 [pii]
AID - 10.1177/0961203311427550 [doi]
PST - ppublish
SO  - Lupus. 2012 Apr;21(4):412-20. doi: 10.1177/0961203311427550. Epub 2011 Nov 10.